Cecilia S Lee1, Aaron Y Lee2, Lakshmi Akileswaran2, David Stroman3, Kathryn Najafi-Tagol3, Steve Kleiboeker4, James Chodosh5, Amalia Magaret6, Anna Wald7, Russell N Van Gelder8. 1. Department of Ophthalmology, University of Washington, Seattle, Washington. Electronic address: leecs2@uw.edu. 2. Department of Ophthalmology, University of Washington, Seattle, Washington. 3. NovaBay Pharmaceuticals, Inc., Emeryville, California. 4. Viracor Eurofins Clinical Diagnostics, Lee's Summit, Missouri. 5. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts. 6. Department of Biostatistics, University of Washington, Seattle, Washington; Department of Laboratory Medicine, University of Washington, Seattle, Washington; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 7. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington; Department of Epidemiology, University of Washington, Seattle, Washington. 8. Department of Ophthalmology, University of Washington, Seattle, Washington; Departments of Biological Structure and Pathology, University of Washington, Seattle, Washington.
Abstract
PURPOSE: To determine host and pathogen factors predictive of outcomes in a large clinical cohort with keratoconjunctivitis. DESIGN: Retrospective analyses of the clinical and molecular data from a randomized, controlled, masked trial for auricloscene for keratoconjunctivitis (NVC-422 phase IIB, NovaBay; clinicaltrials.gov identifier, NCT01877694). PARTICIPANTS: Five hundred participants from United States, India, Brazil, and Sri Lanka with clinical diagnosis of keratoconjunctivitis and positive rapid test results for adenovirus. METHODS: Clinical signs and symptoms and bilateral conjunctival swabs were obtained on days 1, 3, 6, 11, and 18. Polymerase chain reaction (PCR) analysis was performed to detect and quantify adenovirus in all samples. Regression models were used to evaluate the association of various variables with keratoconjunctivitis outcomes. Time to resolution of each symptom or sign was assessed by adenoviral species with Cox regression. MAIN OUTCOME MEASURES: The difference in composite scores of clinical signs between days 1 and 18, mean visual acuity change between days 1 and 18, and time to resolution of each symptom or sign. RESULTS: Of 500 participants, 390 (78%) showed evidence of adenovirus by PCR. Among adenovirus-positive participants, adenovirus D species was most common (63% of total cases), but a total of 4 species and 21 different types of adenovirus were detected. Adenovirus D was associated with more severe signs and symptoms, a higher rate of subepithelial infiltrate development, and a slower decline in viral load compared with all other adenovirus species. The clinical courses of all patients with non-adenovirus D species infection and adenovirus-negative keratoconjunctivitis were similar. Mean change in visual acuity between days 1 and 18 was a gain of 1.9 letters; worse visual outcome was associated with older age. CONCLUSIONS: A substantial proportion of keratoconjunctivitis is not associated with a detectable adenovirus. The clinical course of those with adenovirus D keratoconjunctivitis is significantly more severe than those with non-adenovirus D species infections or adenovirus-negative keratoconjunctivitis; high viral load at presentation and non-United States origin of participants is associated with poorer clinical outcome.
RCT Entities:
PURPOSE: To determine host and pathogen factors predictive of outcomes in a large clinical cohort with keratoconjunctivitis. DESIGN: Retrospective analyses of the clinical and molecular data from a randomized, controlled, masked trial for auricloscene for keratoconjunctivitis (NVC-422 phase IIB, NovaBay; clinicaltrials.gov identifier, NCT01877694). PARTICIPANTS: Five hundred participants from United States, India, Brazil, and Sri Lanka with clinical diagnosis of keratoconjunctivitis and positive rapid test results for adenovirus. METHODS: Clinical signs and symptoms and bilateral conjunctival swabs were obtained on days 1, 3, 6, 11, and 18. Polymerase chain reaction (PCR) analysis was performed to detect and quantify adenovirus in all samples. Regression models were used to evaluate the association of various variables with keratoconjunctivitis outcomes. Time to resolution of each symptom or sign was assessed by adenoviral species with Cox regression. MAIN OUTCOME MEASURES: The difference in composite scores of clinical signs between days 1 and 18, mean visual acuity change between days 1 and 18, and time to resolution of each symptom or sign. RESULTS: Of 500 participants, 390 (78%) showed evidence of adenovirus by PCR. Among adenovirus-positive participants, adenovirus D species was most common (63% of total cases), but a total of 4 species and 21 different types of adenovirus were detected. Adenovirus D was associated with more severe signs and symptoms, a higher rate of subepithelial infiltrate development, and a slower decline in viral load compared with all other adenovirus species. The clinical courses of all patients with non-adenovirus D species infection and adenovirus-negative keratoconjunctivitis were similar. Mean change in visual acuity between days 1 and 18 was a gain of 1.9 letters; worse visual outcome was associated with older age. CONCLUSIONS: A substantial proportion of keratoconjunctivitis is not associated with a detectable adenovirus. The clinical course of those with adenovirus D keratoconjunctivitis is significantly more severe than those with non-adenovirus D species infections or adenovirus-negative keratoconjunctivitis; high viral load at presentation and non-United States origin of participants is associated with poorer clinical outcome.
Authors: Robert Sambursky; Shachar Tauber; Frank Schirra; Kristian Kozich; Richard Davidson; Elisabeth J Cohen Journal: Ophthalmology Date: 2006-10 Impact factor: 12.079
Authors: Mark R Wilkins; Sharmina Khan; Catey Bunce; Anthony Khawaja; Dilani Siriwardena; Daniel F P Larkin Journal: Br J Ophthalmol Date: 2011-01-20 Impact factor: 4.638
Authors: Adriana G Maranhão; Caroline C Soares; Maria Carolina M Albuquerque; Norma Santos Journal: Rev Inst Med Trop Sao Paulo Date: 2009 Jul-Aug Impact factor: 1.846
Authors: Gurdeep Singh; Xiaohong Zhou; Jeong Yoon Lee; Mohammad A Yousuf; Mirja Ramke; Ashrafali M Ismail; Ji Sun Lee; Christopher M Robinson; Donald Seto; David W Dyer; Morris S Jones; Jaya Rajaiya; James Chodosh Journal: Virology Date: 2015-09-07 Impact factor: 3.616
Authors: Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh Journal: FEBS Lett Date: 2019-12-11 Impact factor: 4.124
Authors: Matthew R Pennington; Amrita Saha; David F Painter; Christina Gavazzi; Ashrafali M Ismail; Xiaohong Zhou; James Chodosh; Jaya Rajaiya Journal: Microorganisms Date: 2019-09-13